In a meta-analysis encompassing nine clinical studies of 1,314 patients and 1,311 control subjects, statistical evidence was insufficient to support the effect of a PPAR-γ agonist on memory improvement in patients with AD and mild-to-moderate AD37. This evidence concerns the gene PPARG and Alzheimer disease.